



### Company Overview

Natus is a leading provider of healthcare products and services used for the screening, detection, treatment, monitoring and tracking of common medical ailments in neurological dysfunction, epilepsy, sleep disorders, newborn care, hearing impairment and balance and mobility disorders.

### Natus Medical Announces the Appointment of Ilan Daskal to the Board of Directors

Mar 20 2020, 8:00 AM EDT

### Update to Natus Medical Fourth Quarter and Full Year 2019 Financial Results

Mar 2 2020, 4:10 PM EST

### The supporting community of Otoscan® expands its global influence

Feb 24 2020, 4:49 PM EST

### Stock Overview

Symbol	NTUS
Exchange	Nasdaq
Market Cap	750.31m
Last Price	\$22.00
52-Week Range	\$18.91 - \$34.88

03/27/2020 04:00 PM EDT

### Investor Relations

Natus Medical Incorporated
Drew Davies
Chief Financial Officer
T: (925) 223-6700
<a href="mailto:InvestorRelations@Natus.com">InvestorRelations@Natus.com</a>

### Management Team

#### Jonathan A. Kennedy

President, Chief Executive Officer and Director

#### Drew Davies

Executive Vice President and Chief Financial Officer

#### Austin F. Noll, III

Executive Vice President and Chief Commercial Officer

#### D. Christopher Chung, M.D.

Vice President of Quality, Regulatory Affairs and Chief Medical Officer

#### Seán Langan

Vice President Global Operations

#### Ivan Pandiyan

Vice President Global Research and Development

#### Lisa Paul

Vice President and Chief People Officer

#### William Hill

General Counsel

### Natus Medical Incorporated

6701 Koll Center Parkway  
Suite 120  
Pleasanton, CA 94566

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.